Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial

Open access

Abstract

In the SELECT cardiovascular outcomes trial, semaglutide showed a 20% reduction in major adverse cardiovascular events in 17,604 adults with preexisting cardiovascular disease, overweight or obesity, without diabetes. Here in this prespecified analysis, we examined effects of semaglutide on weight and anthropometric outcomes, safety and tolerability by baseline body mass index (BMI). In patients treated with semaglutide, weight loss continued over 65 weeks and was sustained for up to 4 years. At 208 weeks, semaglutide was associated with mean reduction in weight (−10.2%), waist circumference (−7.7 cm) and waist-to-height ratio (−6.9%) versus placebo (−1.5%, −1.3 cm and −1.0%, respectively; P < 0.0001 for all comparisons versus placebo). Clinically meaningful weight loss occurred in both sexes and all races, body sizes and regions. Semaglutide was associated with fewer serious adverse events. For each BMI category (<30, 30 to <35, 35 to <40 and ≥40 kg m − 2 ) there were lower rates (events per 100 years of observation) of serious adverse events with semaglutide (43.23, 43.54, 51.07 and 47.06 for semaglutide and 50.48, 49.66, 52.73 and 60.85 for placebo). Semaglutide was associated with increased rates of trial product discontinuation. Discontinuations increased as BMI class decreased. In SELECT, at 208 weeks, semaglutide produced clinically significant weight loss and improvements in anthropometric measurements versus placebo. Weight loss was sustained over 4 years. ClinicalTrials.gov identifier: NCT03574597 .

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-024-02996-7

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Percentage change in mean body weight from baseline through week 208 for all patients in-trial21 and first on-treatment. a,b, Observed data from the in-trial period (a) and first on-treatment (b). The symbols are the observed means, and error bars are ±s.e.m. Numbers shown below each panel represent the number of patients contributing to the means. Analysis of covariance with treatment and baseline values was used to estimate the treatment difference. Exact P values are 1.323762 × 10−94 and 9.80035 × 10−100 for a and b, respectively. P values are two-sided and are not adjusted for multiplicity. ETD, estimated treatment difference; sema, semaglutide.
Fig. 1 Percentage change in mean body weight from baseline through week 208 for all patients in-trial21 and first on-treatment. a,b, Observed data from the in-trial period (a) and first on-treatment (b). The symbols are the observed means, and error bars are ±s.e.m. Numbers shown below each panel represent the number of patients contributing to the means. Analysis of covariance with treatment and baseline values was used to estimate the treatment difference. Exact P values are 1.323762 × 10−94 and 9.80035 × 10−100 for a and b, respectively. P values are two-sided and are not adjusted for multiplicity. ETD, estimated treatment difference; sema, semaglutide.CC BY · PubMed Central
Fig. 2 Variation in weight loss response for semaglutide andplacebo. a, Categorical weight loss from baseline at week 104 for semaglutide and placebo. Data from the in-trial period. Bars depict the proportion (%) of patients receiving semaglutide or placebo who achieved ≥5%, ≥10%, ≥15%, ≥20% and ≥25% weight loss. b,c, Percentage change in body weight for individual patients from baseline to week 104 for semaglutide (b) and placebo (c). Each patient’s percentage change in body weight is plotted as a single bar.
Fig. 2 Variation in weight loss response for semaglutide andplacebo. a, Categorical weight loss from baseline at week 104 for semaglutide and placebo. Data from the in-trial period. Bars depict the proportion (%) of patients receiving semaglutide or placebo who achieved ≥5%, ≥10%, ≥15%, ≥20% and ≥25% weight loss. b,c, Percentage change in body weight for individual patients from baseline to week 104 for semaglutide (b) and placebo (c). Each patient’s percentage change in body weight is plotted as a single bar.CC BY · PubMed Central
Fig. 3 Proportion (%) of in-trial patients achieving sex- and race-specific WC cutoff points for increased metabolic risk according to baseline BMI <35 or ≥35 kg m−2. WC cutoff points; Asian women <80 cm, non-Asian women <88 cm, Asian men <88 cm, non-Asian men <102 cm.
Fig. 3 Proportion (%) of in-trial patients achieving sex- and race-specific WC cutoff points for increased metabolic risk according to baseline BMI <35 or ≥35 kg m−2. WC cutoff points; Asian women <80 cm, non-Asian women <88 cm, Asian men <88 cm, non-Asian men <102 cm.CC BY · PubMed Central
Fig. 4 Change in BMI category (healthy, overweight, class I obesity, class II obesity and class III obesity) at baseline and week 104 for in-trial patients. In the semaglutide group, 12.0% of patients achieved normal weight status at week 104 (from 0% at baseline), compared with 1.2% (from 0% at baseline) for placebo. BMI classes: healthy (BMI <25 kg m−2), overweight (25 to <30 kg m−2), class I obesity (30 to <35 kg m−2), class II obesity (35 to <40 kg m−2) and class III obesity (BMI ≥40 kg m−2).
Fig. 4 Change in BMI category (healthy, overweight, class I obesity, class II obesity and class III obesity) at baseline and week 104 for in-trial patients. In the semaglutide group, 12.0% of patients achieved normal weight status at week 104 (from 0% at baseline), compared with 1.2% (from 0% at baseline) for placebo. BMI classes: healthy (BMI <25 kg m−2), overweight (25 to <30 kg m−2), class I obesity (30 to <35 kg m−2), class II obesity (35 to <40 kg m−2) and class III obesity (BMI ≥40 kg m−2).CC BY · PubMed Central
Fig. 5 Effect of semaglutide treatment or placebo on mean percentage change in body weight from baseline to week 104 by subgroups. Data from the in-trial period. N = 17,604. P values represent test of no interaction effect. P values are two-sided and are not adjusted for multiplicity. The dots show estimated treatment differences, and the error bars show 95% CIs. Details of the statistical models are available in Methods. ETD, estimated treatment difference; HbA1c, glycated hemoglobin; MI, myocardial infarction; PAD, peripheral artery disease; sema, semaglutide.
Fig. 5 Effect of semaglutide treatment or placebo on mean percentage change in body weight from baseline to week 104 by subgroups. Data from the in-trial period. N = 17,604. P values represent test of no interaction effect. P values are two-sided and are not adjusted for multiplicity. The dots show estimated treatment differences, and the error bars show 95% CIs. Details of the statistical models are available in Methods. ETD, estimated treatment difference; HbA1c, glycated hemoglobin; MI, myocardial infarction; PAD, peripheral artery disease; sema, semaglutide.CC BY · PubMed Central
Fig. 6 AEs leading to trial product discontinuation for baseline BMI class (<30 kg m−2, 30 to <35 kg m−2, 35 to <40 kg m−2, and ≥40 kg m−2); cumulative incidence for first event over time (left) and cumulative mean number of events over time (right). Data are in-trial from the full analysis set. sema, semaglutide.
Fig. 6 AEs leading to trial product discontinuation for baseline BMI class (<30 kg m−2, 30 to <35 kg m−2, 35 to <40 kg m−2, and ≥40 kg m−2); cumulative incidence for first event over time (left) and cumulative mean number of events over time (right). Data are in-trial from the full analysis set. sema, semaglutide.CC BY · PubMed Central
Extended Data Fig. 1 Effect of semaglutide treatment or placebo on waist circumference from baseline to week 104 by subgroups. Data from the in-trial period. N = 17,604. P values represent test of no interaction effect. P values are two-sided and not adjusted for multiplicity. The dots show estimated treatment differences and the error bars show 95% confidence intervals. Details of the statistical models are available in Methods. BMI, body mass index; CI, confidence interval; CV, cardiovascular; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; ETD, estimated treatment difference; HbA1c, glycated hemoglobin; MI, myocardial infarction; PAD, peripheral artery disease; sema, semaglutide.
Extended Data Fig. 1 Effect of semaglutide treatment or placebo on waist circumference from baseline to week 104 by subgroups. Data from the in-trial period. N = 17,604. P values represent test of no interaction effect. P values are two-sided and not adjusted for multiplicity. The dots show estimated treatment differences and the error bars show 95% confidence intervals. Details of the statistical models are available in Methods. BMI, body mass index; CI, confidence interval; CV, cardiovascular; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; ETD, estimated treatment difference; HbA1c, glycated hemoglobin; MI, myocardial infarction; PAD, peripheral artery disease; sema, semaglutide.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

7 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Research works printed but not linked: 1

  1. Tchang, B. G. et al. Pharmacologic treatment of overweight and obesity in adults. in (eds. Feingold, K. R. et al.) Endotext https://www.ncbi.nlm.nih.gov/books/NBK279038/ (MDText.com, 2000).

Cited by

See all 427

Metadata

Authors
Ryan, D. H., Lingvay, I., Deanfield, J., Kahn, S. E., Barros, E., Burguera, B., Colhoun, H. M., Cercato, C., Dicker, D., Horn, D. B., Hovingh, G. K., Jeppesen, O. K., Kokkinos, A., Lincoff, A. M., Meyhöfer, S. M., Oral, T. K., Plutzky, J., van Beek, A. P., Wilding, J. P. H., & Kushner, R. F.
Affiliations
  • Pennington Biomedical Research Center (US)
  • The University of Texas Southwestern Medical Center (US)
  • University College London (GB)
  • University of Washington (US)
  • Novo Nordisk (Denmark) (DK)
  • Cleveland Clinic (US)
  • Institute of Genetics and Cancer (GB)
  • Tel Aviv University (IL)
  • National and Kapodistrian University of Athens (GR)
  • University of Lübeck (DE)
  • Brigham and Women's Hospital (US)
  • University of Liverpool (GB)
  • Northwestern University (US)
Corresponding author
Ryan, Donna H.
Venue
Nature Medicine
Published
2024-05-13
Volume
30
Issue
7
Pages
2049-2057
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4396850943
Cited by
347
References
25
Citations by year
2026: 143 · 2025: 154 · 2024: 50
FWCI
98.58
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, cc-by)
  • Digital Commons-TMC (Texas Medical Center) (submittedVersion)
  • Pure Amsterdam UMC (submittedVersion, cc-by)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by)
Funders
Novo Nordisk A/S
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
semaglutide, weight loss, sustained weight loss, waist circumference, waist-to-height ratio, anthropometric outcomes, body mass index, serious adverse events, drug safety and tolerability, GLP-1 receptor agonists, SELECT trial
MeSH terms
Semaglutide, Adult, Aged, Cardiovascular Diseases, Double-Blind Method, Glucagon-Like Peptides, Female, Humans, Male, Middle Aged, Obesity, Weight Loss, Body Mass Index, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. https://app.cochat.ai/papers/10.1038/s41591-024-02996-7
The paper
Ryan, D. H., Lingvay, I., Deanfield, J., Kahn, S. E., Barros, E., Burguera, B., Colhoun, H. M., Cercato, C., Dicker, D., Horn, D. B., Hovingh, G. K., Jeppesen, O. K., Kokkinos, A., Lincoff, A. M., Meyhöfer, S. M., Oral, T. K., Plutzky, J., van Beek, A. P., Wilding, J. P. H., & Kushner, R. F. (2024). Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nature Medicine. https://doi.org/10.1038/s41591-024-02996-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.